Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Ibogaine
Ibogaine is a naturally-occurring psychedelic of the iboga alkaloid class. It comes from the root bark of Tabernanthe iboga, used in Central African spiritual traditions for centuries. It acts on opioid, serotonin, and glutamate brain systems simultaneously, producing its unusual anti-addictive effects.[1][2][3]
Ibogaine is a naturally-occurring oneirogen of the iboga alkaloid class. Derived from Tabernanthe iboga root bark, it is distinguished from classical psychedelics by its waking-dream character and multi-day duration. Ibogaine acts on κ-opioid,[1] NMDA,[2] SERT, and nicotinic acetylcholine[3] targets, producing its effects through convergent modulation of multiple addiction-relevant circuits.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Ibogaine was first isolated in 1901, but the Bwiti people of Central Africa used iboga root bark in spiritual ceremonies long before. Howard Lotsof discovered its anti-addictive potential in 1962; the US classified it Schedule I in 1970, and clinical development stalled. A 2024 trial in veterans showed large PTSD benefits,[4] and a 2026 executive order is now accelerating US regulatory review.
Subjective effects include waking visions of personal memories, emotional catharsis, panoramic autobiographical recall, and a detached observer-like perspective on one's own life. The experience is unlike any classical psychedelic — rather than distorting the outside world, ibogaine generates an internal dream-cinema of personal memories. Severe loss of coordination, persistent nausea, and complete sleep suppression are unavoidable physical effects.
Ibogaine does not cause physical dependence,[5] but it can trigger fatal heart arrhythmia at therapeutic doses by blocking a cardiac electrical channel.[6] This risk extends for days after ingestion because the metabolite noribogaine clears slowly; opioids, heart medications, and common antidepressants amplify it significantly. Clinical evidence is building but rests on open-label studies — no large placebo-controlled trial has been completed.
History[edit]
Discovery
Ibogaine was first isolated from Tabernanthe iboga root bark in 1901.citation needed The Bwiti people of Gabon and Cameroon had used the bark in initiation ceremonies for centuries before its isolation.[7][8] Its anti-addictive potential was discovered in 1962 when Howard Lotsof took it and found his heroin cravings had vanished; he patented the application in 1985.[9]
Clinical significance
US federal research ran from 1991 to 1995 and the FDA authorized an experimental drug application in 1993, but NIDA ended the program after high-dose rat studies raised concerns about brain damage. Deborah Mash continued open-label work at Caribbean clinics, publishing the largest prospective clinical series in 2018.[10]
Prohibition and modern use
Ibogaine was classified Schedule I in the US around 1967, formalized under the Controlled Substances Act of 1970. New Zealand made it available by prescription in 2009. A 2024 Stanford trial in Nature Medicine demonstrated large benefits for veterans with PTSD,[4] Texas allocated $50 million for FDA clinical research, and a 2026 executive order has accelerated regulatory review and patient access.[9][11]
The name ibogaine derives from iboga, from the Fang and Mitsogho languages of Gabon. In Bwiti tradition the root bark is consumed during initiation as a sacrament — contact with ancestors and the spirit world, not therapy.
Chemistry[edit]
Structural class
Ibogaine belongs to the iboga alkaloid family — a class of compounds built on an indole ring fused to a complex bridged ring system, structurally distinct from tryptamine and phenethylamine psychedelics. Its molecular formula is C₂₀H₂₆N₂O (molecular weight 310.4 g/mol).
Most commercial ibogaine is produced by semi-synthesis from voacangine, an alkaloid found in Voacanga africana at much higher concentrations than in T. iboga itself.[13]
Pharmacology[edit]
Mechanism of action
Ibogaine acts on several addiction-relevant brain systems at once: it activates kappa-opioid receptors,[1] blocks glutamate signaling,[2] inhibits serotonin reuptake, and blocks nicotinic acetylcholine receptors.[3] No single mechanism explains the full anti-addictive effect — the convergence of all of them does.[14]
A key downstream effect is the release of GDNF — a growth factor that supports long-term repair of dopamine neurons — in the brain's reward circuit.[15] Noribogaine, ibogaine's main metabolite, also triggers GDNF release, extending this effect for days after a single dose.[16]
Pharmacokinetics
The liver enzyme CYP2D6 converts ibogaine to noribogaine, which lasts far longer in the body — 28–49 hours versus ibogaine's 1–10 hours[17] — sustaining both therapeutic activity and cardiac risk. People with reduced CYP2D6 activity, whether genetic or caused by certain antidepressants, accumulate roughly twice the drug exposure[18] and face elevated cardiac risk.[18]
Neuroscience[edit]
Where it acts
In the brain's reward center, ibogaine suppresses dopamine activity — opposing the surges that drugs of abuse produce.[19][20] In the area that drives motivation, ibogaine and its metabolite noribogaine trigger the release of GDNF, a growth factor that supports long-term repair of dopamine neurons.[15][16]
Why it matters
The leading theory is that ibogaine reopens a critical period for reward learning — restoring the brain's capacity to form new associations after addiction has made circuits pathologically rigid.[21] Rather than blocking a specific drug receptor, this model holds that ibogaine resets the brain's ability to relearn reward patterns through GDNF-driven structural change.
- Does cerebellar damage occur in humans? In rats, large injected doses cause selective death of cerebellar cells,[22] but typical human doses are well below that threshold.[23] No brain imaging studies have examined this in people.[24]
- What sustains the anti-addictive effect? Benefits often last weeks to months — far beyond noribogaine's clearance. GDNF-mediated brain remodeling is the leading hypothesis, but direct human evidence is lacking.
- Can the effect work without the visionary experience? The derivative 18-MC retains some anti-addictive efficacy without psychoactivity but lacks GDNF induction, leaving the question unresolved.
Subjective Effects[edit]
Ibogaine generates an experience that turns inward rather than distorting external perception. It takes the form of a waking dream — a lucid, narrative review of personal memories watched from a detached observer perspective.[25] Physical surroundings recede completely, and the content is shaped by psychological preparation and intention more than by the immediate environment.[26][27]
Among commonly known psychedelics, ibogaine has no close parallel. Where psilocybin and LSD amplify incoming perception, ibogaine replaces it with an entirely internally generated cinema. The physical burden is also far heavier than any classical psychedelic — severe loss of coordination and persistent nausea accompany the experience throughout.
Howard Lotsof discovered ibogaine's anti-addictive properties in 1962 when he and five heroin-dependent friends reported elimination of craving after a single dose. Classified Schedule I in 1970, clinical development stalled for decades despite NIDA-funded research and open-label Caribbean studies. The 2024 Stanford MISTIC trial demonstrated large effect sizes for PTSD and TBI in veterans,[4] and a 2026 executive order has accelerated regulatory review.
Subjective effects include waking-dream imagery, panoramic autobiographical recall, emotional catharsis, and prolonged introspection. The experience is fundamentally oneiric — a sustained, internally generated narrative in which personal memories are reviewed from a detached observer perspective, with greater mystical experience intensity predicting larger therapeutic outcomes.[5] Severe ataxia, persistent nausea, bradycardia, and complete sleep suppression are characteristic unsought effects.
Ibogaine produces no physical dependence and does not support self-administration in animal models,[6] but its primary acute risk — fatal cardiac arrhythmia from hERG channel blockade — occurs at therapeutic doses.[7] The active metabolite noribogaine extends cardiac risk for 48–72 hours after ingestion, and individuals with reduced CYP2D6 activity face approximately doubled exposure. Clinical evidence is growing but rests on open-label studies; no randomized placebo-controlled trial at full psychedelic doses has been completed.
History[edit]
Discovery
Ibogaine was first isolated from Tabernanthe iboga root bark in 1901 by French chemists Dybowski and Landrin.citation needed The root bark had been used for centuries in Bwiti religious practices among the Fang people of Gabon and Cameroon — for initiation rites, spiritual ceremonies, and as a low-dose stimulant.[8][9] Its anti-addictive properties remained unknown until 1962, when 19-year-old Howard Lotsof and five heroin-dependent friends self-administered ibogaine and reported elimination of craving and withdrawal after roughly 30 hours; Lotsof was awarded US Patent No. 4,499,096 in 1985 for this application.[10]
Clinical significance
The US National Institute on Drug Abuse funded a preclinical ibogaine research program from 1991 to 1995, and the FDA authorized an Investigational New Drug application in 1993. NIDA terminated the program after cerebellar neurotoxicity findings in rats at high doses. Deborah Mash continued open-label observations at Caribbean facilities, publishing the largest prospective clinical series in 2018.[11]
Prohibition and modern use
Ibogaine was classified as Schedule I in the United States circa 1967, formalized under the Controlled Substances Act of 1970. New Zealand became the first country to make it legally available by physician prescription in 2009. A surge of clinical activity from 2021 onward produced high-profile publications including the Stanford MISTIC study in Nature Medicine (2024), Texas allocated $50 million for FDA-regulated clinical research, and a 2026 executive order instructed acceleration of research, regulatory review, and patient access through Right to Try pathways.[10][12]
The name ibogaine derives from iboga, itself from the Fang and Mitsogho languages of Gabon. In Bwiti tradition the root bark is consumed during initiation as a sacrament — the experience is understood as contact with ancestors and the spirit world, not as recreation or therapy.
Chemistry[edit]
Structural class
Ibogaine belongs to the monoterpenoid indole alkaloid family, sharing the ibogamine skeleton with voacangine, tabernanthine, and coronaridine. The indole nucleus fused to an isoquinuclidine ring system defines the iboga alkaloid class, distinguishing it structurally from tryptamine, ergoline, and phenethylamine psychedelics. The 7-methoxy group on the indole ring differentiates ibogaine from ibogamine, which lacks this substitution.
Molecular identity
| Molecular formula | C₂₀H₂₆N₂O |
| Molecular weight | 310.4 g/mol |
The pentacyclic ring system comprises a fused indole, an isoquinuclidine bridged bicyclic unit, and a cyclohexane ring bearing an ethyl substituent. The full IUPAC name — (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0²·¹⁰.0⁴·⁹.0¹³·¹⁸]nonadeca-2(10),4(9),5,7-tetraene — reflects this complexity.
Stereochemistry
Ibogaine possesses four stereocenters. The naturally occurring form is (−)-ibogaine, the biologically active enantiomer found in T. iboga. No published human pharmacological data on the (+)-enantiomer exist.[14]
Natural occurrence and sourcing
Ibogaine is the principal psychoactive alkaloid of T. iboga root bark, occurring at low concentration — typically below 1% by dry weight. The related species Voacanga africana produces voacangine, an iboga alkaloid convertible to ibogaine by semi-synthesis, in substantially higher yields and serves as the preferred commercial starting material.[15]
No efficient enantioselective total synthesis of ibogaine exists. The compound is obtained either by direct extraction from T. iboga (low yield) or by semi-synthesis from voacangine. Ibogaine free base is lipophilic with limited water solubility; the hydrochloride salt form is substantially more soluble and is the standard preparation for clinical and research use.[16]
Pharmacology[edit]
Mechanism of action
Ibogaine is a multi-target compound with no single dominant receptor. Its anti-addictive effects arise from simultaneous action on several addiction-relevant systems: κ-opioid agonism,[1] NMDA open-channel antagonism,[2] SERT inhibition, and nicotinic acetylcholine receptor antagonism.[3] Partial reversal by both a kappa antagonist and an NMDA agonist confirms that these two mechanisms operate together in vivo.[17]
A key downstream effect is upregulation of glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area. GDNF injection into this region mimics ibogaine's anti-alcohol effect, while anti-GDNF antibodies block it.[18] Noribogaine, ibogaine's primary metabolite, also induces GDNF,[19] extending neurotrophic signaling into the long post-dose phase.
Ibogaine inhibits the serotonin transporter, acutely increasing extracellular serotonin in the nucleus accumbens — an action specifically linked to reduction of alcohol intake.[20][21] Simultaneously, it decreases dopamine in the nucleus accumbens and blocks morphine- and nicotine-induced dopamine release,[20][22] though it paradoxically enhances cocaine-induced dopamine elevation.[22]
Ibogaine and noribogaine function as mu-opioid receptor antagonists with no agonist activity, ruling out direct opioid-type effects.[23] Nicotinic acetylcholine receptor antagonism is implicated in reduction of nicotine intake.[20] An emerging hypothesis proposes that ibogaine reopens critical periods for reward learning through GDNF-mediated neuroplasticity and extracellular matrix reorganization.[24]
Pharmacokinetics
Ibogaine is rapidly absorbed after oral administration and distributes extensively into the central nervous system — brain-to-plasma ratio reaches 3.4 in animal models.[25] The compound also sequesters in adipose tissue, creating a reservoir for slow release and prolonged pharmacological effects.[26] P-glycoprotein and BCRP transporters limit oral bioavailability through hepatobiliary and intestinal excretion.[25]
The liver enzyme CYP2D6 converts ibogaine to noribogaine through O-demethylation. CYP2D6 genotype strongly correlates with drug exposure[27] — poor metabolizers, whether genetic or drug-induced (e.g. by paroxetine), exhibit approximately 2-fold higher active moiety exposure, necessitating dose reduction and ideally pre-treatment genotyping.[27]
Ibogaine itself has a relatively short half-life of 1–10 hours depending on metabolizer status. Noribogaine persists far longer at 28–49 hours,[28] sustaining both therapeutic activity and cardiac risk for days after a single oral dose. Human pharmacokinetic-pharmacodynamic relationships have been characterized in a Dutch opioid use disorder detoxification cohort.[29]
Neuroscience[edit]
Where it acts
Ibogaine modulates the brain's reward circuitry across multiple neurotransmitter systems simultaneously. In the nucleus accumbens — the core hub of reward processing — it acutely reduces dopamine release, opposing the dopamine surges produced by drugs of abuse.[20][22] It blocks both morphine- and nicotine-induced dopamine release, though it paradoxically enhances cocaine-induced dopamine elevation,[22] indicating a mechanism more complex than simple dopamine suppression.
In the ventral tegmental area, ibogaine and its metabolite noribogaine upregulate GDNF, a neurotrophic factor that supports long-term remodeling of dopamine neurons.[18][19] At high doses in animal models, ibogaine activates inferior olivary neurons, causing excitotoxic damage to cerebellar Purkinje cells[30] — an effect that occurs well above the therapeutic dose range.[31]
Why it matters
The leading theoretical framework proposes that ibogaine reopens critical periods for reward learning — restoring plasticity in circuits that have become pathologically rigid through addiction.[24] Rather than blocking a specific drug-receptor interaction, this model holds that ibogaine resets the brain's capacity to relearn reward associations through GDNF-mediated neuroplasticity.
An alternative view holds that ibogaine's efficacy derives from convergence of multiple partial effects — kappa agonism reducing drug reward salience, NMDA antagonism disrupting conditioned associations, serotonin modulation affecting mood and craving — each insufficient alone but collectively producing the observed anti-addictive profile.
- Does cerebellar damage occur in humans? The rodent neurotoxic threshold (75–100 mg/kg injected) is substantially above typical human doses, but no neuroimaging studies have examined cerebellar integrity after clinical ibogaine treatment.[32]
- What sustains the anti-addictive effect? Patients report benefit lasting weeks to months — far beyond noribogaine's elimination. GDNF-mediated neuroplasticity is the leading hypothesis, but direct human evidence is lacking.
- Can anti-addictive effects be separated from the psychedelic experience? The derivative 18-MC retains some anti-addictive efficacy without psychoactivity but lacks GDNF induction. Whether the full ibogaine effect requires the visionary experience is unknown.
Subjective Effects[edit]
Ibogaine's character is fundamentally oneiric rather than psychedelic in the classical serotonergic sense. External sensory input recedes as internally generated autobiographical content takes over — a sustained waking dream shaped more by personal history and therapeutic intention than by environment. Set and setting operate differently here: psychological preparation and intention direct the narrative content of the visionary phase, while physical setting matters primarily for safety during the severe physical impairment that accompanies it.[33][34]
The ibogaine experience has no close parallel among commonly known psychedelics. Where psilocybin and LSD amplify and distort incoming perception, ibogaine generates an entirely internal cinema — a lucid, narrative review of personal memories viewed from a detached observer perspective.[35] The somatic burden is also far heavier than any classical psychedelic, with severe ataxia and persistent nausea defining the physical experience throughout.
Effect Grid
At common doses (10–20 mg/kg oral), the full ibogaine experience emerges. The dominant feature is an oneiric waking-dream state: vivid, panoramic autobiographical imagery — "life review" scenes from personal history arising with eyes open or closed. This is qualitatively distinct from geometric or entity-contact hallucinations of serotonergic psychedelics. Intense introspection, emotional catharsis, and existential insight characterize the cognitive dimension. Time distortion is profound.
Physically, severe ataxia renders standing and walking impossible; patients must remain supine throughout. Nausea and vomiting are common during onset. Bradycardia is consistent and dose-dependent. Sleep is suppressed for 24–36 hours.
This is the addiction-treatment dose range used in clinical settings. The experience demands 36–48 hours of committed time and medical monitoring. QTc prolongation risk is clinically significant.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Light sensitivity · Proprioceptive distortion · Vestibular distortion · Perspective distortion · Color alteration · Auditory distortion · Brightness alteration · Sound sensitivity · Tinnitus · Visual drifting · Auditory misinterpretation · Depth perception distortion · Visual haze / noise · Visual morphing · Color enhancement · Tracers · After-images · Geometry · Peripheral vision distortion · Visual acuity suppression · Visual breathing · Touch suppression · Music enhancement · Visual melting · Synesthesia · Symmetrical texture repetition · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations · Object transformations · Perspective hallucinations
Perspective distortion · Color alteration · Auditory distortion · Brightness alteration · Sound sensitivity · Tinnitus · Visual drifting · Auditory misinterpretation · Depth perception distortion · Visual haze / noise · Visual morphing · Color enhancement · Tracers · After-images · Geometry · Peripheral vision distortion · Visual acuity suppression · Visual breathing · Touch suppression · Music enhancement · Visual melting · Synesthesia · Symmetrical texture repetition · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations · Object transformations · Perspective hallucinations
Insomnia · Nystagmus (eye wobbles) · Physical fatigue · Sedation · Pupil dilation · Spontaneous body sensations · Involuntary body movements · Appetite suppression · Bodily heaviness · Heart rate perception changes · Trembling · Vomiting · Abnormal heartbeat · Muscle tension · Body schema distortion · Excessive sweating · Tingling / electric sensations · Stimulation · Dehydration sensation · Breathing alteration · Headache · Restlessness · Vibrations / buzzing · Constipation · Pain suppression · Salivation · Diarrhea · Sexual arousal enhancement · Bodily dissociation
Sedation · Pupil dilation · Spontaneous body sensations · Involuntary body movements · Appetite suppression · Bodily heaviness · Heart rate perception changes · Trembling · Vomiting · Muscle tension · Body schema distortion · Excessive sweating · Tingling / electric sensations · Stimulation · Dehydration sensation · Breathing alteration · Headache · Restlessness · Vibrations / buzzing · Constipation · Pain suppression · Salivation · Diarrhea · Sexual arousal enhancement · Bodily dissociation
Immersion enhancement · Cognitive fatigue · Confusion · Thought disorganization · Novelty enhancement · Focus suppression · Information processing suppression · Openness enhancement · Memory enhancement · Thought loops · Pattern recognition enhancement · Conceptual thinking · Cognitive dysphoria · Multiple thought streams · Thought connectivity · Cognitive flexibility · Memory fragmentation · Analysis enhancement · Motivation enhancement · Increased nature relatedness · Synchronicity · Creativity enhancement · Thought organization · Delusions · Delirium · Amnesia
Thought disorganization · Novelty enhancement · Focus suppression · Information processing suppression · Openness enhancement · Memory enhancement · Thought loops · Pattern recognition enhancement · Conceptual thinking · Cognitive dysphoria · Multiple thought streams · Thought connectivity · Cognitive flexibility · Memory fragmentation · Analysis enhancement · Motivation enhancement · Increased nature relatedness · Synchronicity · Creativity enhancement · Thought organization · Delirium · Amnesia
Anxiety · Simultaneous emotions · Dysphoria · Empathy enhancement · Irritability · Euphoria
Irritability · Euphoria
Derealization · Emotional susceptibility · Social disconnection · Self-control enhancement · Social connection · Trust enhancement · Identity alteration · Cognitive disconnection · Boundary dissolution · Ego dissolution
Social connection · Trust enhancement · Identity alteration · Cognitive disconnection · Boundary dissolution · Ego dissolution
Transpersonal visions · Entity contact · Transpersonal feelings · Near-death experience · Non-dual awareness · Voidness · Cessation
Non-dual awareness · Voidness · Cessation
Lucidity enhancement · Recursive awareness
Timeline
First effects emerge as mild nausea, slight perceptual brightening, and building bodily awareness. The wide onset range (30 minutes to 3 hours) reflects variable oral absorption and CYP2D6 metabolizer status.
Nausea intensifies. Ataxia develops rapidly, requiring the supine position. Early visual disturbances and internal imagery begin.
The full oneiric waking-dream state dominates: vivid panoramic autobiographical imagery, life review scenes, and deep introspective engagement. Severe ataxia, bradycardia, and tremor persist. Sleep is impossible.
Oneiric imagery gradually fades, replaced by sustained introspection and emotional processing. Physical symptoms begin to ease but ataxia and nausea may persist. Wakefulness continues.
Cognitive clarity slowly returns. Motor coordination improves but remains impaired. Residual visual phenomena and emotional sensitivity persist.
A prolonged afterglow lasting 1–3 days features emotional openness, reflective mood, mild cognitive changes, and continued integration of the experience. Noribogaine remains pharmacologically active (t1/2 28–49 hours), sustaining subtle effects and maintaining cardiac risk.
⚠ Do not drive or operate heavy machinery for at least 72 hours after ibogaine ingestion; impairment from noribogaine persists well beyond subjective resolution.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Cardiac risk (primary)
Ibogaine and noribogaine both block the hERG channel at concentrations reached during therapeutic use.[6][28] Multiple deaths have been documented, most attributed to a fatal rhythm called torsades de pointes progressing to cardiac arrest.[29][30] Noribogaine's long half-life means the cardiac danger window extends days after ibogaine itself has cleared.[28][29]
The Stanford MISTIC protocol used magnesium as cardiac protection; no unexpected serious adverse events occurred in 30 participants.[4] Reversible QT prolongation was documented in a Dutch opioid detox study,[7] noribogaine alone produces dose-dependent QT prolongation,[31] and arrhythmia has followed unregulated internet-purchased ibogaine.[32]
Cerebellar neurotoxicity
In rats, very high injected doses cause selective death of cerebellar nerve cells.[22] Human therapeutic doses are substantially below that threshold,[23] and no human neuroimaging studies have examined whether this occurs in people.[24]
Acute physical effects
Severe loss of coordination makes walking impossible during the acute phase — patients must remain lying down.[7] Nausea and vomiting are common at onset. Heart rate slows dose-dependently,[20] and sleep is suppressed for 24–36 hours.
Psychological Risks
Published clinical studies have not reported persistent psychosis or lasting perceptual disturbances after ibogaine. The experience can involve intense emotional content including traumatic memories, and psychological distress during the session is expected. No controlled data on adverse psychological outcomes exist — available evidence comes from screened observational series.
Tolerance & Dependence
Ibogaine does not support self-administration in animal models,[5] and no human cases of ibogaine dependence or compulsive redosing have been reported. The standard clinical model — single or widely-spaced doses — means tolerance cannot be meaningfully assessed from existing data.
Drug Interactions
CYP2D6 inhibitors (high risk)
Common antidepressants including paroxetine, fluoxetine, bupropion, and duloxetine block CYP2D6, the liver enzyme that breaks down ibogaine. Paroxetine roughly doubles ibogaine exposure in the bloodstream,[18] concentrating both cardiac and psychedelic risk. People with genetically low CYP2D6 activity face the same elevated exposure without taking any inhibitor.[18]
QT-prolonging medications (high risk)
Many medications stretch the heart's electrical recharge time — the same mechanism as ibogaine. Combining them creates additive risk that can be lethal. These include certain antipsychotics (haloperidol, ziprasidone), heart rhythm medications (quinidine, sotalol, amiodarone), antibiotics (azithromycin, fluoroquinolones), methadone, and tricyclic antidepressants.
Opioids (high risk)
During ibogaine treatment, patients cannot walk or protect their airway. If opioids are present and breathing slows, the inability to move becomes life-threatening. One early fatality was attributed to covert heroin use during ibogaine treatment.[12] A complete opioid washout is required before any session.
Serotonergic drugs
Ibogaine blocks serotonin reuptake. Adding SSRIs, MAOIs, or serotonin-releasing agents on top of that can trigger dangerous serotonin overload — overheating, rapid heart rate, and seizures. No published cases of this combination exist, but concurrent serotonergic medication should be stopped before treatment.
P-glycoprotein inhibitors
Drugs that inhibit the P-glycoprotein transporter (verapamil, cyclosporine) may increase how much ibogaine reaches the brain.[33] Clinical significance has not been characterized.
Contraindications
8 knownAbsolute
- Pre-existing QT prolongation — baseline QTc >450 ms (men) or >470 ms (women)[29][30]
- Irregular heartbeat or structural heart disease[29][30]
- Concurrent QT-prolonging medication
- Concurrent opioid use — requires complete washout[12]
Relative
- Severe liver impairment — impaired metabolism may unpredictably alter drug exposure
- Low potassium or magnesium — correct before treatment[7][25]
- CYP2D6 inhibitor use without dose adjustment[18]
- Pregnancy — no safety data existsafety citation needed
Harm Reduction[edit]
Forms & Identification
Ibogaine circulates as hydrochloride salt powder or capsules, sourced from T. iboga root bark extraction or semi-synthesis from voacangine. Total alkaloid extracts (TA) contain ibogaine alongside other iboga alkaloids at variable ratios — precise dosing is unreliable. Purified ibogaine HCl is the preferred clinical form.
Reagent testing alone cannot establish safety. The margin between therapeutic and cardiotoxic exposure is too narrow to trust unverified material — quantitative purity analysis is essential for any preparation. If using a total alkaloid extract, the ibogaine content is uncertain and the effective dose cannot be reliably calculated.
Guidelines
- Obtain a baseline ECG and cardiac clearance before any ibogaine session
- Complete CYP2D6 genotyping if available — poor metabolizers require significant dose reduction
- Discontinue all QT-prolonging medications, opioids, SSRIs, and CYP2D6 inhibitors with appropriate washout periods
- Correct any electrolyte imbalances (potassium, magnesium) before treatment
- Fast for 8–12 hours before ingestion to reduce nausea
- Ensure continuous cardiac monitoring (at minimum pulse oximetry and heart rate) for the first 24 hours, ideally 48 hours
- Have at least one experienced sitter present for the full duration — plan for 36+ hours of supervision
- Keep the space quiet, dimly lit, and free from interruption
- Provide water and electrolytes for the recovery phase
- Do not attempt to stand or walk during the acute phase — severe loss of coordination makes falls a serious risk
Set & Setting
The severe physical impairment of the acute phase makes setting fundamentally different from shorter-acting psychedelics. Patients cannot walk — lying down is mandatory. A private, quiet space with a bed is essential, and continuous monitoring by an experienced sitter or medical professional is the minimum safety requirement given the cardiac risk window.
Therapeutic intention and psychological preparation substantially shape the oneiric content. Pre-session work with a therapist — clarifying intentions, reviewing personal history — improves both experience quality and outcomes. The visionary state will surface autobiographical material including potentially traumatic memories, and psychological readiness for this content is critical.
Aftercare & integration. The 24–72 hours following the acute phase are a period of continued psychological processing. Sleep will return gradually — do not force it. Light meals, hydration, and quiet company support physical recovery.
The oneiric experience often surfaces deeply personal material that benefits from structured reflection. Journaling, conversation with a trusted person, or sessions with an integration therapist help consolidate insights.
Many clinical programs schedule integration sessions in the days and weeks following treatment. If disturbing material arose during the experience, professional support is especially valuable — do not process traumatic content alone.
Recovery & Support
Ibogaine is an intervention, not a cure. The window of reduced craving that follows — often lasting weeks to months — is an opportunity to establish new patterns. Aftercare programs, peer support, and ongoing therapy substantially improve long-term outcomes.
For those using ibogaine in the context of opioid dependence, connection with addiction medicine specialists and recovery communities before treatment ensures continuity of care. Organizations such as the Global Ibogaine Therapy Alliance provide information and referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Ibogaine's physical effects — nausea, inability to walk, slowed heart rate — are expected and do not alone indicate crisis. Seek immediate medical help for: chest pain or pressure, fainting or loss of consciousness, seizure, heart rate below 40 bpm or irregular rhythm, breathing difficulty, or unresponsiveness.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present
- 2. Place the person on their side (recovery position) to protect the airway
- 3. Do not leave them alone
- 4. Do not induce vomiting
- 5. Monitor breathing and heart rate continuously while waiting for help
What to tell the dispatcher: Report that the person has taken ibogaine, the approximate dose and time of ingestion, and current symptoms — especially any cardiac symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Ibogaine is federally prohibited in the United States and several European countries, available by physician prescription in New Zealand, and unregulated or accessible through treatment centers in a handful of other jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act, 1970) | Federally prohibited since ~1967; no accepted medical use under current scheduling. Texas allocated $50M for FDA clinical research (2025); 2026 executive order accelerating research and Right to Try access[9][11] |
| New Zealand | Non-approved medicine (prescription) | Available by physician prescription since 2009; case-by-case justification and clinical supervision required |
| Canada | Prescription Drug (Food and Drug Regulations) | Theoretically accessible via Special Access Program; approvals rare in practice |
| United Kingdom | Prohibited (Psychoactive Substances Act 2016) | Blanket prohibition; no medical exemptions |
| France | Prohibited | No medical exemptions |
| Belgium | Prohibited | No medical exemptions |
| Sweden | Prohibited | No medical exemptions |
| Switzerland | Prohibited | No medical exemptions |
| Portugal | Decriminalized (personal possession since 2001) | Commercial treatment operations remain illegal |
| Mexico | Unregulated | Treatment centers operate in legal gray area; not explicitly prohibited or formally approved |
| Costa Rica | Unregulated | No legal restrictions[34] |
| The Bahamas | Permitted for clinical use | Established treatment centers with US-standard medical protocols |
| Australia | Regulated (TGA oversight) | Not explicitly scheduled on SUSMP but regulated as prescription-only; effectively not clinically available |
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Cardiac risk (primary)
Both ibogaine and noribogaine block the hERG channel at concentrations reached during therapeutic use.[7] This has been confirmed in human heart cells, where both compounds delay electrical recovery.[36] Noribogaine's longer half-life means cardiac risk extends days after ibogaine itself has been eliminated.[36][37]
Clinical monitoring confirms the risk: reversible QT prolongation and slowed heart rate were documented in a Dutch opioid detoxification study,[8] noribogaine produced dose-dependent QT prolongation,[38] and prolonged irregular heartbeat has been reported following internet-purchased ibogaine.[39]
Multiple fatalities have been reported in the literature,[37][40] attributed primarily to torsades de pointes progressing to cardiac arrest. No formal lethal dose has been established in humans or animals.safety citation needed The Stanford MISTIC protocol co-administers magnesium as a cardiac protective measure; no unexpected serious adverse events occurred in 30 participants.[4]
Cerebellar neurotoxicity
In rats, high doses of ibogaine (75–100 mg/kg injected) cause selective death of cerebellar Purkinje cells through an excitotoxic mechanism involving excessive glutamate release.[30] Sigma-2 receptor activation mediates this pathway.[20] The no-observed-adverse-effect level is 25 mg/kg,[32] and the standard anti-addictive dose (40 mg/kg) does not produce cell loss above controls.[31]
Human therapeutic doses (~10–25 mg/kg oral) are substantially below the rodent toxic threshold, but interspecies dose extrapolation is uncertain. No human neuroimaging studies have examined cerebellar integrity after ibogaine treatment.
Acute physical effects
Severe loss of coordination renders patients unable to walk during the acute phase; lying down is mandatory.[8] Nausea and vomiting are common during onset. Dose-dependent slowing of heart rate is consistently reported.[22] Ibogaine suppresses sleep for 24–36 hours.
Psychological Risks
Published clinical studies have not reported persistent psychosis or HPPD (HPPD) after ibogaine administration. The oneiric experience can involve intense emotional content — autobiographical scenes may include traumatic memories — and psychological distress during the acute phase is expected in clinical settings.
No controlled data on the incidence of adverse psychological outcomes exist. Available evidence is limited to observational series where patients were screened and monitored before and during treatment.
Tolerance & Dependence
Ibogaine does not support self-administration in animal models,[6] and no human cases of ibogaine dependence or compulsive redosing have been reported. The clinical paradigm of single or widely-spaced doses precludes standard tolerance assessment.
Cross-tolerance with other psychedelics or kappa agonists has not been specifically investigated. The absence of tolerance literature reflects the single-dose treatment model rather than evidence that tolerance cannot develop.
Drug Interactions
CYP2D6 inhibitors (high risk)
Drugs that inhibit CYP2D6 — including paroxetine, fluoxetine, bupropion, and duloxetine — significantly increase ibogaine exposure. Paroxetine approximately doubles the amount of active drug in the bloodstream.[27] Individuals with genetically reduced CYP2D6 activity face the same elevated exposure and cardiac risk unless doses are reduced.[27]
QT-prolonging medications (high risk)
Additive QT prolongation occurs with co-administered QT-prolonging drugs: certain antipsychotics (haloperidol, ziprasidone), heart rhythm medications (quinidine, sotalol, amiodarone), antibiotics (azithromycin, fluoroquinolones), methadone, and tricyclic antidepressants. The combination is potentially lethal given ibogaine's own hERG channel blockade.
Opioids (high risk)
Concurrent opioid use creates complex and potentially lethal risk. Ibogaine-induced loss of coordination prevents airway protection during respiratory slowing. One fatality in early clinical studies was attributed to possible covert heroin use during ibogaine treatment.[13] A complete opioid washout period is required before ibogaine administration.
Serotonergic drugs
Ibogaine's SERT inhibition creates theoretical serotonin syndrome risk with concurrent SSRIs, MAOIs, or serotonin-releasing agents. No published cases of ibogaine-induced serotonin syndrome exist, but concurrent serotonergic medication should be discontinued before treatment.
P-glycoprotein inhibitors
Drugs that inhibit the P-glycoprotein transporter (verapamil, cyclosporine) may increase ibogaine absorption and brain penetration.[25] Clinical significance has not been characterized.
Contraindications
8 knownAbsolute
- Pre-existing QT prolongation — baseline QTc >450 ms (men) or >470 ms (women)[37][40]
- Irregular heartbeat or structural heart disease[37][40]
- Concurrent QT-prolonging medication
- Concurrent opioid use — requires complete washout[13]
Relative
- Severe liver impairment — impaired metabolism may unpredictably alter drug exposure
- Low potassium or magnesium — correct before treatment[8][35]
- CYP2D6 inhibitor use without dose adjustment[27]
- Pregnancy — no safety data existsafety citation needed
Harm Reduction[edit]
Forms & Identification
Ibogaine circulates primarily as hydrochloride salt powder or capsules, sourced either from direct extraction of T. iboga root bark or semi-synthesis from voacangine. Total alkaloid extracts (TA) contain ibogaine alongside other iboga alkaloids at variable ratios, making dose precision difficult — purified ibogaine HCl is the preferred clinical form.
Given the narrow margin between therapeutic and cardiotoxic exposure, reagent testing alone cannot establish safety. Quantitative purity analysis is essential for any ibogaine preparation. If using a total alkaloid extract, the ibogaine content is uncertain and the effective dose cannot be reliably calculated.
Guidelines
- Obtain a baseline ECG and cardiac clearance before any ibogaine session
- Complete CYP2D6 genotyping if available — poor metabolizers require significant dose reduction
- Discontinue all QT-prolonging medications, opioids, SSRIs, and CYP2D6 inhibitors with appropriate washout periods
- Correct any electrolyte imbalances (potassium, magnesium) before treatment
- Fast for 8–12 hours before ingestion to reduce nausea
- Ensure continuous cardiac monitoring (at minimum pulse oximetry and heart rate) for the first 24 hours, ideally 48 hours
- Have at least one experienced sitter present for the full duration — plan for 36+ hours of supervision
- Keep the space quiet, dimly lit, and free from interruption
- Provide water and electrolytes for the recovery phase
- Do not attempt to stand or walk during the acute phase — severe loss of coordination makes falls a serious risk
Set & Setting
Ibogaine's 18–36 hour peak duration and severe physical impairment make setting considerations fundamentally different from shorter-acting psychedelics. A private, quiet space with immediate access to a bed or mat is essential — patients cannot walk during the acute phase. Continuous monitoring by an experienced sitter or medical professional is not optional; it is a minimum safety requirement given the cardiac risk window.
Therapeutic intention and psychological preparation substantially shape the oneiric content. Pre-session work with a therapist or experienced facilitator — clarifying intentions, reviewing personal history, and establishing trust — improves both the subjective experience and therapeutic outcomes. The waking-dream state will surface autobiographical material including potentially traumatic memories; psychological readiness for this is critical.
Aftercare & integration. The 24–72 hours following the acute phase are a period of continued psychological processing. Sleep will return gradually — do not force it. Light meals, hydration, and quiet company support physical recovery.
The oneiric experience often surfaces deeply personal material that benefits from structured reflection. Journaling, conversation with a trusted person, or sessions with an integration therapist help consolidate insights. Many clinical programs schedule integration sessions in the days and weeks following treatment. If disturbing material arose during the experience, professional support is especially valuable — do not attempt to process traumatic content alone.
Recovery & Support
Ibogaine is used as an intervention for substance dependence, not as a standalone cure. The window of reduced craving that follows treatment — often lasting weeks to months — is an opportunity to establish new patterns, not a permanent resolution. Aftercare programs, peer support groups, and ongoing therapeutic relationships substantially improve long-term outcomes.
For those using ibogaine in the context of opioid dependence, connection with addiction medicine specialists and recovery communities before treatment ensures continuity of care. Organizations such as the Global Ibogaine Therapy Alliance provide information and referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Ibogaine's physical effects — nausea, inability to walk, slowed heart rate — are expected and do not alone indicate crisis. Seek immediate medical help for: chest pain or pressure, fainting or loss of consciousness, seizure, heart rate below 40 bpm or irregular rhythm, breathing difficulty, or unresponsiveness.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present
- 2. Place the person on their side (recovery position) to protect the airway
- 3. Do not leave them alone
- 4. Do not induce vomiting
- 5. Monitor breathing and heart rate continuously while waiting for help
What to tell the dispatcher: Report that the person has taken ibogaine, the approximate dose and time of ingestion, and current symptoms — especially any cardiac symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Ibogaine occupies a fragmented international regulatory landscape. No international treaty specifically schedules ibogaine, leaving regulation to national governments. It is a Schedule I controlled substance in the United States, prohibited in several European countries, and legally available by prescription or unregulated in a small number of jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act, 1970) | Federally prohibited since ~1967; no accepted medical use under current scheduling. Texas allocated $50M for FDA clinical research (2025); 2026 executive order accelerating research and Right to Try access[10][12] |
| New Zealand | Non-approved medicine (prescription) | Available by physician prescription since 2009; case-by-case justification and clinical supervision required |
| Canada | Prescription Drug (Food and Drug Regulations) | Theoretically accessible via Special Access Program; approvals rare in practice |
| United Kingdom | Prohibited (Psychoactive Substances Act 2016) | Blanket prohibition; no medical exemptions |
| France | Prohibited | No medical exemptions |
| Belgium | Prohibited | No medical exemptions |
| Sweden | Prohibited | No medical exemptions |
| Switzerland | Prohibited | No medical exemptions |
| Portugal | Decriminalized (personal possession since 2001) | Commercial treatment operations remain illegal |
| Mexico | Unregulated | Treatment centers operate in legal gray area; not explicitly prohibited or formally approved |
| Costa Rica | Unregulated | No legal restrictions[41] |
| The Bahamas | Permitted for clinical use | Established treatment centers with US-standard medical protocols |
| Australia | Regulated (TGA oversight) | Not explicitly scheduled on SUSMP but regulated as prescription-only; effectively not clinically available |
The regulatory trajectory is shifting rapidly in the United States. Multiple states have introduced ibogaine research or access legislation, and federal action via executive order has prioritized scheduling review contingent on Phase 2/3 trial completion and FDA evaluation.
Frequently asked questions
What is Ibogaine?
Ibogaine is a monoterpenoid indole alkaloid from Tabernanthe iboga root bark, classified as an oneirogenic hallucinogen. It acts on kappa-opioid, NMDA, serotonin transporter, and nicotinic receptor systems and is under clinical investigation for addiction and PTSD.
How long does Ibogaine last?
Total duration by route of administration — Oral: 18 – 36 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Ibogaine?
Psychedex publishes a dosage table for Ibogaine on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Ibogaine?
The highest-severity documented interactions for Ibogaine: GHB, GBL (Lethal), Local anesthetics (Lethal), Opioids (Lethal), Stimulants (Lethal), 5-HTP, Tryptophan (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Ibogaine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Ibogaine: tolerance builds none. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abDeecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD (1992) Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies — Brain research PMID:1377086
- [2] ^abChen K, Kokate TG, Donevan SD, Carroll FI, Rogawski MA (1996) Ibogaine block of the NMDA receptor: in vitro and in vivo studies — Neuropharmacology PMID:8793904
- [3] ^abSweetnam PM, Lancaster J, Snowman A, Collins JL, Perschke S, Bauer C, Ferkany J (1995) Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity — Psychopharmacology PMID:7568622
- [4] ^abcCherian KN, Keynan JN, Anker L, et al. (2024) Magnesium-ibogaine therapy in veterans with traumatic brain injuries — Nature medicine doi:10.1038/s41591-023-02705-w
- [5] ^abBelgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR (2016) Ibogaine and addiction in the animal model, a systematic review and meta-analysis — Translational psychiatry doi:10.1038/tp.2016.71
- [6] ^abAlper K, Bai R, Liu N, Fowler SJ, Huang XP, Priori SG, Ruan Y (2016) hERG Blockade by Iboga Alkaloids — Cardiovascular toxicology doi:10.1007/s12012-015-9311-5
references
- [1] ^abDeecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD (1992) Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies — Brain research PMID:1377086
- [2] ^abChen K, Kokate TG, Donevan SD, Carroll FI, Rogawski MA (1996) Ibogaine block of the NMDA receptor: in vitro and in vivo studies — Neuropharmacology PMID:8793904
- [3] ^abSweetnam PM, Lancaster J, Snowman A, Collins JL, Perschke S, Bauer C, Ferkany J (1995) Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity — Psychopharmacology PMID:7568622
- [4] ^abCherian KN, Keynan JN, Anker L, et al. (2024) Magnesium-ibogaine therapy in veterans with traumatic brain injuries — Nature medicine doi:10.1038/s41591-023-02705-w
- [5] ^Brown RE, Lissemore JI, Shinozuka KF, et al. (2026) Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans — Journal of affective disorders doi:10.1016/j.jad.2025.120722
- [6] ^abBelgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR (2016) Ibogaine and addiction in the animal model, a systematic review and meta-analysis — Translational psychiatry doi:10.1038/tp.2016.71